Treace Medical Concepts, INC.: directors' dealings · United States · SEC (Form 4)

About Treace Medical Concepts, INC.

Treace Medical Concepts, Inc. is a U.S.-based medical technology company listed on the NASDAQ in the United States under the ticker TMCI. Headquartered in Ponte Vedra, Florida, Treace focuses on foot and ankle surgery, with a highly specialized franchise in bunion correction and midfoot deformity repair. The company was founded in 2014 and has built its identity around a 3D correction approach designed to address not only the visible bunion deformity, but also the underlying biomechanical instability that drives recurrence. The company’s core commercial engine is the Lapiplasty® platform, a combination of instruments, implants, and surgical workflow designed to enable reproducible triplanar bunion correction and, in Treace’s positioning, faster return to weight bearing than some traditional procedures. Over time, Treace broadened its portfolio with Adductoplasty®, which targets midfoot adductus deformity and osteoarthritis, as well as minimally invasive or percutaneous offerings such as Nanoplasty®, Percuplasty™, and Micro-Lapiplasty®. It has also expanded its implant and instrumentation ecosystem, including plate systems and procedure-specific trays. This creates a relatively concentrated business model: Treace is not a broad orthopedics company, but a focused innovator in a narrow and clinically defined sub-segment. From a competitive perspective, Treace competes against larger orthopedic and device companies, but its niche positioning is a key differentiator. Its competitive advantages are centered on proprietary technology, surgeon training and education, and a workflow that aims to make complex bunion surgery more standardized, efficient, and reproducible. The company primarily sells to foot and ankle surgeons, ambulatory surgery centers, hospitals, and other specialized care settings. Its commercial footprint is overwhelmingly in the United States, although its clinical messaging and product development are relevant to broader global medtech trends. Recent developments highlight continued product innovation. Treace has recently announced new product enhancements and, in 2026, reported the first surgical case using Lapiplasty Lightning™ technology. At the same time, recent financial updates through 2024 and 2025 suggest a business that is still investing heavily in innovation and commercial expansion while navigating pressure on profitability and changing growth expectations. For investors, TMCI should be viewed as a specialized U.S. medtech name on the NASDAQ, with a differentiated franchise in bunion and midfoot surgery, meaningful product momentum, and execution risk tied to adoption rates, surgeon conversion, and market acceptance of its next-generation systems.